[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, cabozantinib has been shown to be effective in the treatment of hepatocellular carcinoma (HCC) in multiple clinical trials. The phase 3 CELESTIAL trial demonstrated that cabozantinib improved overall survival and progression-free survival in patients with advanced HCC who had previously received sorafenib. Additionally, analysis of subgroups showed that even elderly patients over 65 years and patients with high baseline alpha-fetoprotein levels benefited from cabozantinib. Other documents also mention the efficacy of cabozantinib in HCC and its approval for this indication. Therefore, the answer is A. yes, cabozantinib is effective for hepatocellular carcinoma.\", \"answer_choice\": \"A\"}"
]